Dr. Rockman-Greenberg is a medical geneticist in the Program of Genetics and Metabolism, Winnipeg Regional Health Authority, and Distinguished Professor, Departments of Pediatrics and Child Health & Biochemistry and Medical Genetics, University of Manitoba. She is a clinician scientist in the Children’s Hospital Research Institute of Manitoba and has led the enzyme replacement therapy clinical trials of asfotase alfa for the treatment of Hypophosphatasia in Canada.

Distinguished professor, Depts. Of Pediatrics and Child Health & Biochemistry and Medical Genetics, University of Manitoba and the Children’s Hospital Research Institute of Manitoba.

Dr. Crine is a former professor in the Department of Biochemistry at the University of Montreal. Dr. Crine was a founder of Enobia Pharma where he served as Chief Scientific Officer and Vice President Research from 2003 until 2012. He is a co-inventor of Asfotase Alfa and was responsible for its preclinical development. He is now a private consultant providing strategic and technological advice to emerging companies developing therapies for rare bone diseases.

Dr. Ward is an Associate Professor of Pediatrics (Faculties of Medicine and Surgery at the University of Ottawa), the Director of the Pediatric Bone Health Clinical and Research Programs, and the Principal Investigator of a Canada-wide research program evaluating the effect of glucocorticoids on bone health in children with leukemia, rheumatic conditions and nephrotic syndrome (called the STeroid-associated Osteoporosis in the Pediatric Population (STOPP) research program). She has received a number of awards for her work on the effects of chronic childhood illnesses on the developing skeleton, including the Canadian Child Health Clinician Scientist Career Development Award, the Canadian Institutes for Health Research New Investigator Award, the Canadian Child Health Clinician Scientist Career Enhancement Award and most recently, a University of Ottawa Research Chair Award.

Jessica Hartley has been a genetic counsellor in the Program of Genetics and Metabolism at the Health Sciences Center since 2009. She received a Masters of Genetic Counselling degree from Northwestern University in 2008 and was certified in Genetic Counselling from the American Board of Genetic Counselling in 2009. In her current position, Jessica works in pediatric metabolics and is an integral part of the Manitoba newborn screening program. She has a specialized interest in the psychosocial impact of childhood-onset metabolic genetic conditions and multidisciplinary & interprofessional care models. She is currently a Lecturer in the Department of Biochemistry & Medical Genetics, College of Medicine, Faculty of Health Sciences, University of Manitoba.

Dr. Rauch is a pediatrician and a clinician scientist in the Dept of Pediatrics at McGill University. His area of expertise is in metabolic bone diseases including Osteogenesis Imperfecta. He works at the Shriners Hospital for Children in Montreal.

Amy has worked as the clinical trials coordinator for Asfotase Alfa at the Winnipeg site in the Children’s Hospital Research Institute of Manitoba since 2010 and has been instrumental in meticulously meeting the needs of all the HPP patients who have participated in clinical trials.

Dr. Sirrs is an adult endocrinologist and is the Medical Director of the Adult Metabolic Disorders Clinic in the Dept of Internal Medicine, University of British Columbia. She specializes in inborn errors of metabolism and, as a clinical trialist, she has been instrumental in the development of clinical practice guidelines for enzyme replacement therapy for a variety of lysosomal storage disorders including Fabry disease.

Mark DeBrincat is a Physiotherapist who specializes in Orthopaedics and Sports Medicine. He lives out his passion for his work and has a thriving private practise in Winnipeg, Manitoba. For 28 years, his unique methods of Orthopaedic manual therapy, Myofacial techniques, Exercise regimes and Acupuncture expertise have been recognized and well sought after. He has had extensive experience and success in treating patients with HPP and is both pleased and honoured to sit on the Scientific Board.

Dr. McKee is a professor at McGill University in Montreal in the Faculties of Dentistry and Medicine. He received his B.Sc. and Ph.D. degrees from McGill University in cell biology, and after a postdoctoral fellowship in the Department of Orthopedic Surgery at Harvard, he held an academic appointment at University of Montreal, after which he moved to McGill University in 1998. Dr. McKee has contributed greatly to our understanding of the causes of dentin and pulp pathology in the teeth of HPP patients.

Dr. Schroth is a dentist and a research scientist at the University of Manitoba. He actively researches the relationship between oral health and vitamin D status especially in First Nations children. He has been an active member of the clinical trials team at the University of Manitoba of Asfotase Alfa for the treatment of HPP.